Paras Biopharmaceuticals Finland Oy is a Finnish biopharmaceuticals company comprising of protein scientists, bioprocess engineers and technologists, who have strong experience in developing biologics in a most efficient manner.Company main activities & offerings are in 3 major areas:
- Contract development & microbial biologics manufacturing (CDMO) – Company offers small scale (10L), medium scale (150L) & large scale (750L) production services. This includes the CDMO of commercial scale production for bispecific antibodies Fab, scFv, dAb and Fc-fusion nanobodies
- Recombinant Bioprocess Enzymes – Paras Biopharmaceuticals has developed and is offering Recombinant Bioprocess enzymes. These include Recombinant Enterokinase (RapidEK®) & Tev Protease (RapidTEV®) which are used in the cleavage of fusion proteins. We are ready to cater to biopharma needs for scale-up / commercial scale production.
- Development & Licensing of Biosimilars – Paras Biopharmaceuticals has developed and is now offering the following Biosimilars: Recombinant Teriparatide (Forteo Biosimilar), Recombinant Anakinra (Kineret Biosimilar), Analog Insulin Aspart, Recombinant Rasburicase (Elitek / Fasturtec Biosimilar) and Recombinant Romiplostim (N-plate Biosimilar). Due to its own developed technologies, the company has achieved efficient and cost effective production of some high value biosimilars. This is based on Paras Biopharmaceuticals’ proprietary platform which includes Diabrid® Technology, Noblecleav® Technology and Biomultifold® Technology.
Paras Biopharmaceuticals fully own a microbial production facility in Finland for the microbial production of recombinant products in microbial strains. With a total floor area of 25,000 ft2
and a classified cleanroom of 4,300 ft2
, our team has strong experience in carrying out microbial biologics production.